trending Market Intelligence /marketintelligence/en/news-insights/trending/thMywbhkAEQaTc1wstjAMw2 content esgSubNav
In This List

Venture capital firm cuts holdings in Oncopeptides

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Venture capital firm cuts holdings in Oncopeptides

Sweden-based venture capital firm Industrifonden sold 3 million Oncopeptides AB (publ) shares to institutional investors.

The shares sold represent about 5.4% of Oncopeptides' existing share capital and voting rights. Oncopeptides said it will not receive any proceeds from the transaction.

As a result of the transaction, Industrifonden now owns 7,420,805 Oncopeptides shares, or about 13.4% of the Swedish pharmaceutical company's existing share capital.

Financial details of the transaction were not disclosed.

Jefferies International Ltd. was the sole book runner for the transaction.